This report identifies key demand-side trends in the life sciences industry that can help enterprises fine-tune their digital strategies. It also provides an overview of enterprise challenges in this space based on Avasant’s assessment.

Why read this Market Insights?

The life sciences industry is under pressure to accelerate time to market and offset the patent cliff, making digital R&D central to pipeline competitiveness. Advances in genomics and regulatory acceptance of real-world evidence are fueling precision medicine, while escalating payor cost containment and tighter price controls are intensifying market access challenges. Rising modality complexity and supply chain volatility demand resilient, digitally enabled manufacturing operations, and Global Capability Centers are shifting from cost arbitrage to innovation-led value creation. To navigate these shifts, enterprises increasingly partner with service providers to drive digital transformation and sustain growth.

The Life Sciences Digital Services 2026 Market Insights™ helps enterprises in this sector identify key market trends and challenges for any digital project they participate in.

Methodology

The industry insights presented in this report are based on our ongoing interactions with enterprise CXOs and other key executives; targeted discussions with service providers, subject matter experts, and Avasant Fellows; analyst insights from primary and secondary research; and lessons learned from consulting engagements.

Table of contents

About the report (Pages 3–5)

Executive summary (Pages 6–9)

• • Scope of coverage
  • Key market drivers and enterprise response
  • Avasant recognizes 27 top-tier service providers supporting the digital transformation of life sciences enterprises

Demand-side trends (Pages 10–15)

• • Life sciences enterprises are deploying AI/ML for target identification, molecule design, trial simulation, and protocol optimization, alongside cloud-based clinical data platforms and digital twins.
  • Life sciences organizations are deploying cloud-based genomic and diagnostics platforms that unify R&D, companion diagnostics, and real-world evidence, enabling biomarker-driven trials and precision patient segmentation.
  • Escalating payor cost-containment measures, tighter government price controls, and growing market access complexity are creating sustained pressure.
  • Organizations are embracing digitally enabled, resilient, and scalable operations, leveraging advanced automation, AI-driven supply chain visibility, and predictive analytics to mitigate volatility, optimize production flows, and enhance responsiveness across global networks.
  • GCCs are evolving from cost-focused hubs to strategic centers of innovation and capability-led value creation.

Key contacts (Page 16)

Read the Research Byte based on this report. Please refer to Avasant’s Life Sciences Digital Services 2026 RadarView™ for detailed insights on the service providers and supply-side trends.